Neovascular glaucoma as a chronic neuroischemic optic neuropathy: the impact of cumulative burden on vision-related quality of life in a 36-month prospective study
Open Access
- 30 September 2026
- journal article
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 32 (3) , 93-101
Abstract
Purpose. To evaluate the impact of treatment burden as a functional marker of chronic neuroischemic optic neuropathy progression on vision-related quality of life in patients with neovascular glaucoma. Methods. This prospective cohort study included 351 patients (351 eyes) with secondary neovascular glaucoma associated with proliferative diabetic retinopathy or retinal vein occlusion. Patients were followed for 36 months. Vision-related quality of life was assessed using the validated NEI VFQ-25 questionnaire at baseline, 12 months, and 36 months. Cumulative Burden Index (CBI) was defined as a composite cumulative measure incorporating both treatment intensity (number of transscleral cyclophotocoagulation (TSCPC) procedures) and disease-related burden (severity of complications present at baseline and during follow-up). Statistical analysis included descriptive statistics, linear and logistic regression, ROC analysis, and multilayer perceptron (MLP) neural network modeling. Results. Patients with successful treatment outcomes (n = 282; 80.3%) demonstrated improvement in vision-related quality of life (ΔQoL = +10.26 ± 6.18), whereas patients with resistant disease (n = 69; 19.7%) showed significant deterioration (ΔQoL = −7.43 ± 6.97; p < 0.001). Higher CBI values were independently associated with lower NEI VFQ-25 scores (β = −1.78; 95% CI −2.57 to −0.99; p < 0.001). The between-group difference corresponded to a very large clinical effect size (Cohen’s d = 2.77). In the logistic regression model, CBI remained an independent predictor of unfavorable treatment outcome (OR = 0.48; 95% CI 0.34–0.68; p < 0.001). The neural network model demonstrated good discriminative performance for outcome prediction (AUC = 0.83; 95% CI 0.78–0.88). Conclusions. The CBI was independently associated with vision-related quality of life in patients with neovascular glaucoma and may serve as an integrated marker of chronic neurovascular disease burden. Increased CBI values were associated with significant functional impairment and a poorer clinical prognosis. Integration of composite clinical indices with machine learning approaches may improve risk stratification, personalized treatment planning, and digital clinical decision support in patients with neovascular glaucoma.Keywords
This publication has 28 references indexed in Scilit:
- The impact of treatment modality on quality of life in glaucoma patients: findings from a clinical survey study in Augusta, GAInternational Ophthalmology, 2025
- Efficacy of slow-coagulation cyclophotocoagulation after failed MicroPulse cyclophotocoagulation in refractory glaucomaLasers in Medical Science, 2025
- Measuring Quality of Life in Diabetic Retinal Disease: A Narrative Review of Available Patient-Reported Outcome MeasuresOphthalmology Science, 2023
- The Burden of Caring for and Treating Glaucoma: The Patient PerspectiveOphthalmology Glaucoma, 2022
- Caspases in retinal ganglion cell death and axon regenerationCell Death Discovery, 2017
- Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040Ophthalmology, 2014
- The Pathophysiology and Treatment of GlaucomaJAMA, 2014
- An Assessment of the Health and Economic Burdens of GlaucomaAmerican Journal of Ophthalmology, 2011
- Neovascular glaucomaProgress in Retinal and Eye Research, 2007
- Quality of life associated with unilateral and bilateral good visionOphthalmology, 2001